Prelude Therapeutics (PRLD) Cash from Financing Activities (2019 - 2026)
Prelude Therapeutics (PRLD) reported Cash from Financing Activities of -$314000.0 for Q1 2026, down 96.25% on a YoY basis from -$8.4 million in Q1 2025, and down 101.26% sequentially from $24.9 million in Q4 2025.
Prelude Therapeutics (PRLD) Cash from Financing Activities (2019 - 2026) Analysis & Trends
Prelude Therapeutics (PRLD) has 8 years of Cash from Financing Activities data on file, last reported at -$314000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Financing Activities fell 96.25% year-over-year to -$314000.0; the trailing twelve-month figure through Mar 2026 stood at $24.7 million (up 9371.43% YoY), and the FY2025 full-year result was $24.8 million, up 20780.0% from the prior year.
- Cash from Financing Activities eased to -$314000.0 in Q1 2026, from $24.9 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $111.3 million in Q2 2023 to a low of -$41.0 million in Q2 2022.
- A 5-year average of $9.5 million and a median of $37000.0 in 2025 frame the typical range for Cash from Financing Activities.
- Across the five-year window, Cash from Financing Activities tumbled 9824.17% in 2022 and surged 73464.71% in 2025, its largest moves.
- Tracing PRLD's Cash from Financing Activities over 5 years: stood at $155000.0 in 2022, then jumped by 16181.94% to $25.2 million in 2023, then slumped by 100.13% to -$34000.0 in 2024, then surged by 73464.71% to $24.9 million in 2025, then tumbled by 101.26% to -$314000.0 in 2026.
- Business Quant data shows PRLD's Cash from Financing Activities at -$314000.0 in Q1 2026, $24.9 million in Q4 2025, and -$5000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | Prelude Therapeutics | 324.30 Mn | 179.71 Mn | - | -314,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -314,000.00 |
| Mar 31, 2026 | -314,000.00 |
| Dec 31, 2025 | 24.94 Mn |
| Dec 31, 2025 | 24.94 Mn |
| Sep 30, 2025 | -5,000.00 |
| Sep 30, 2025 | -5,000.00 |
| Jun 30, 2025 | 37,000.00 |
| Jun 30, 2025 | 37,000.00 |
| Mar 31, 2025 | -160,000.00 |
| Mar 31, 2025 | -160,000.00 |
| Dec 31, 2024 | -34,000.00 |
| Dec 31, 2024 | -34,000.00 |
| Sep 30, 2024 | -131,000.00 |
| Sep 30, 2024 | -131,000.00 |
| Jun 30, 2024 | 59,000.00 |
| Jun 30, 2024 | 59,000.00 |
| Mar 31, 2024 | -14,000.00 |
| Mar 31, 2024 | -14,000.00 |
| Dec 31, 2023 | 25.24 Mn |
| Dec 31, 2023 | 25.24 Mn |